Neuron Biopharma, S.A. filed its Annual on Apr 30, 2013 for the period ending Dec 31, 2012. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
2017 | Neuron BioLabs, S.L. cancelled the acquisition of diagnostics operations, R&D services and patents of Alzheimer's disease from Neuron Bio, SA. | CI |
2017 | Neol Biosolutions Seeks Investors | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 5.19M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.16% | 21.83B | |
-11.09% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- NEU Stock
- News Neuron Bio, S.A.
- Neuron Biopharma, S.A. Auditor Raises 'Going Concern' Doubt